Review Article
Covered Stents versus Uncovered Stents for Unresectable Malignant Biliary Strictures: A Meta-Analysis
Table 1
Baseline characteristics of studies included in the meta-analysis.
| | Author/(yr) | Type | Group | Covering material | Number | M/F | Mean age (yr) | Tumor etiology | Pancreatic cancer
(%) | Cholangiocarcinoma
(%) | Ampullary cancer
(%) | Gallbladder cancer
(%) | Metastatic lymph nodes
(%) | Unknown
(%) |
| |
Kullman et al. 2010 [2] | RCT | CSEMS | Polycarbonate-polyurethane | 188 | 88/112 | 79.0 (39–100) | 152 (76) | 12 () | 8 () | 8 () | 16 () | 4 () | | UCSEMS | 191 | 91/109 | 76.0 (51–95) | 155 (77) | 10 () | 9 () | 3 () | 18 () | 5 () | |
Gwon et al. 2010 [7] | NRCT | CSEMS | PTFE | 58 | 37/21 | 63.8 (35–84) | 18 (31.0) | 11 (19.0) | — | 6 (10.3) | 19 (32.8) | 4 (6.9) | | UCSEMS | 58 | 39/19 | 62.7 (24–86) | 17 (29.3) | 16 (27.6) | — | 5 (8.6) | 19 (32.8) | 1 (1.7) | |
Krokidis et al. 2010 [8] | RCT | CSEMS | Viabil | 30 | 20/10 | 66.5 (52–78) | — | 30 (100) | — | — | — | — | | UCSEMS | 30 | 16/14 | 63.7 (46–73) | — | 30 (100) | — | — | — | — | |
Krokidis et al. 2011 [9] | RCT | CSEMS | ePTFE/FEP | 40 | 17/23 | 65.0 ± 8.8 | 35 (87.5) | — | — | — | — | — | | UCSEMS | 40 | 36/4 | 63.5 ± 9.8 | 32 (80) | — | — | — | — | — | |
Li et al. 2012 [10] | NRCT | CSEMS | ePTFE | 35 | 20/15 | 64.4 ± 11.3 | 5 (14.3) | 22 (62.9) | 5 (14.3) | 1 (5.9) | — | 2 (2.6) | | UCSEMS | 47 | 30/17 | 63.2 ± 11.5 | 9 (19.1) | 31 (65.9) | 6 (12.8) | 0 (0.0) | — | 1 (2.2) | |
Kitano et al. 2013 [11] | RCT | CSEMS | Antimigration | 60 | 25/35 | 70.6 ± 10.7 | 60 (100) | — | — | — | — | — | | UCSEMS | 60 | 29/31 | 68.7 ± 8.9 | 60 (100) | — | — | — | — | | |
Ung et al. 2015 [12] | RCT | CSEMS | Hanaro | 34 | 18/16 | 77.0 (54–88) | 30 (88) | — | 1 () | 2 () | — | 2 (5.9) | | UCSEMS | 34 | 9/15 | 79.0 (54–92) | 27 (79) | — | 3 () | 5 () | — | 1 (2.9) | |
Yang et al. 2015 [13] | RCT | CSEMS | Silicone | 51 | 34/17 | 68.7 ± 11.2 | 29 (56.9) | 17 (33.3) | 2 (3.9) | 2 (3.9) | 1 () | — | | UCSEMS | 52 | 30/22 | 68.0 ± 11.3 | 36 (69.2) | 7 (13.5) | 2 (3.8) | 5 (9.6) | 2 (3.8) | — |
|
|
RCT: randomized control trial; NRCT: nonrandomized control trial; CSEMS: covered self-expandable metallic stents; UCSEMS: uncovered self-expandable metallic stents; M: male; F: female.
|
